A Phase 4 interventional study of Pittsburgh Compound B (C-11 PiB) and F-18 FDG in Alzheimer's Disease, Dementia With Lewy Bodies and Frontotemporal Dementia, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 30 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Alzheimer Disease by Mayo Clinic — 8 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Mayo Clinic.
Among the 21 studies in Alzheimer Disease by Mayo Clinic, this one has the largest planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 4, and was the 2nd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →8 of the 21 studies in Alzheimer Disease by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 50–95 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
Mayo Clinic · Sites in United States
Ages 50–90
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 30 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8,000 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 57 across the 17 interventional studies, 195 across the 4 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
7 of the studies in Alzheimer Disease by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04785300Mayo ClinicALSENLITE: Senolytics for Alzheimer's Disease | 2026-12 |
| NCT04002583Mayo Clinic48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease | 2026-12 |
| NCT04099823Mayo ClinicMR Evaluation of Cerebrospinal Fluid (CSF) Dynamics | 2027-01 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
| NCT00950430Mayo ClinicImaging of Brain Amyloid Plaques in the Aging Population | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 21 studies in Alzheimer Disease by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to ascertain the relationship between change in amyloid burden over time, and concurrent change in clinical status.
Identification of risk factors and biomarkers of neurodegenerative disease is essential in caring for the growing numbers of elderly. Imaging biomarkers provide non-invasive ways to look at brain function. A new PET imaging agent, Pittsburgh Compound B (PiB), that identifies brain amyloid is an exciting development in brain imaging that needs to be studied. We plan to study this imaging technique in normal volunteers and patients with a variety of neurodegenerative diseases to determine its utility. Long term followup of these subjects will allow us to understand the predictive ability of this new test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Pittsburgh Compound B (C-11 PiB) · Drug: F-18 FDG · Drug: Tau (18-F-AV-1451)
Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
1. PIB PET scan, Tau PET scan and/or FDG PET scan 2. Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan.
To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.
Time frame: up to 20 years
Using PiB-PET, to ascertain cross-sectionally the magnitude and the spatial distribution of amyloid deposition in the brain in subjects who are clinically classified as CN, MCI, and demented.
Time frame: up to 20 years
To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.
Time frame: up to 20 years
To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.
Time frame: up to 20 years
To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.
Time frame: up to 20 years
The record gives a start of Apr 2008, a primary completion of Jun 2027 and a completion of Jun 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pittsburgh compound B